Breast Cancer Now
Tracked across 2 events · 13 articles · First seen Aug 04, 2026 · Last active Sep 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Supported the study and called for NICE to consider the findings in its guideline review, emphasizing the need for investment in family history services.
Aug 04, 2026 · 6 articles
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: The charity led over two years of campaigning for Enhertu access and hailed the decision as a milestone victory while noting patients died waiting.
Sep 16, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Breast Cancer Now live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard